Low Importance post: Troponin, page-31

Hi Ultra

You're asking the wrong person, as I'm neither a financial analyst or market analyst.

Gut feel tells me the sell down is primarily impatient retail investors exiting, maybe because they lost their appetite for risk & uncertainty, maybe due to a lack of research and understanding, maybe they bought into the hype when the SP was rising without enough DD to understand the product or pace that the biotech segment moves at.

The market values the company at 12.5c a share.
I did a personal 10 year financial plan 3 year ago with the dream of retiring in 2020. In it I made some forecast about where I hopped each of my investment would be at the end of each year.
For EOY 2014 I put ADO at 30c, but personally I'm not that concerned about the current value, because I'm looking at the bigger picture of what is going on, I understand the product & IP, and I believe ADO's future SP value will be many multiple higher than it is currently, which is why I haven't sold any shares.

IMO
Cheers
Muz